US OptionsDetailed Quotes
BEAM241220C70000
- 0.05
- 0.000.00%
15min DelayClose Nov 18 16:00 ET
0.05High0.05Low
0.05Open0.05Pre Close2 Volume57 Open Interest70.00Strike Price10.00Turnover150.19%IV190.42%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier32DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0151Delta0.0035Gamma482.40Leverage Ratio-0.0062Theta0.0003Rho7.27Eff Leverage0.0027Vega
Beam Therapeutics Stock Discussion
Sign in to post a comment
As the U.S. presidential election approaches in just two months, focus intensifies on the crucial debate between Vice President Kamala Harris and former President Donald Trump, scheduled for 9 p.m. ET on Tuesday, September 10. For investors strategizing around the "Trump trade" or the "Harris trade," the market's forward-looking reaction to their governing policies is critical. The election outcome will shape expectations of their administra...
+1
45
11
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
7
$Beam Therapeutics (BEAM.US)$ Will double to 90 dollars 💸 💵 💲
1
2
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
7
Beam Therapeutics' CEO, John Evans showed confidence in Ms. Shaw's ability to turn scientific innovations into commercial treatments. Shaw recognizes Beam's groundbreaking work in genetic medicine and gene editing, predicting major clinical milestones ahead thanks to the company's comprehensive platform and capabilities.
Columns Gene Editing: Is This "Turning Point in Medicine" a Potential Source of Blockbuster Revenue?
The first treatment based on CRISPR technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
19
2
Analysts convey bullish views on the company's prospects, with reduced estimated losses and upgraded revenue estimates. However, issues like dilutive stock issuance hint at potential risks.
$Beam Therapeutics (BEAM.US)$ Beam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250M Upfront
Dow Jones· 4 mins ago![]()
Dow Jones· 4 mins ago
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
Bunny R :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
TheOracleOfBroMaha : If Harris wins im selling everything & investing in Gold
Tonyco :
Joe P :
tough Platypus_9271 : Harris will say anything to get elected . She has no experience in anything but a prosecutor for California and you see how that went. The emergent.czar , you see how that went too. If she is president, she will not be in charge, she knows nothing about the job, and you really want her to sit down with Putin? This is the worst time to even consider her. Watch the debate tonight at 9 eastern time.
View more comments...